Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and
prevention of many conditions, including gastroesophageal reflux disease, gastric and …

Optically active sulfoxides are important compounds for medicinal and pharmaceutical
chemistry. Driven by the increasing demand for efficient, selective and environmentally …

The application of pharmacogenetics holds great promise for individualized therapy.
However, it has little clinical reality at present, despite many claims. The main problem is that …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …

Proton pump inhibitors such as omeprazole (esomeprazole), lansoprazole, pantoprazole
and rabeprazole are eliminated by the hepatic route and the polymorphic CYP2C19 is …

CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize
about 18% of currently available drugs. Some of the important groups of drugs that are …

Many marketed drugs are chiral and are administered as the racemate, a 50: 50
combination of two enantiomers. Pharmacodynamic and pharmacokinetic differences …